The recent demonstration of PitNETs (especially functioning ones) showing the presence of tumor-infiltrating T lymphocytes [50,51,52] and expressing programmed death ligand 1 (PD-L1), a potential biomarker of response to immune checkpoint inhibitors therapy [50,51], raised the hope of possible efficacy of immune checkpoint inhibitors in these tumors. This evidence concerns the gene CD274 and neoplasm.